BIONIME CORPORATIONBB

BIONIME CORPORATION

63.7TWDD
−0.4−0.62%
As of today at 05:35 GMT
TWD
No trades
See on Supercharts

4737 fundamentals

Key facts

Market capitalization‪3.78 B‬TWD
Basic EPS (TTM)−1.36TWD
Founded2003
Employees (FY)‪1.06 K‬
CEOChun Mu Huang
About

Bionime Corp. engages in the manufacturing and selling of medical instruments, providing biotechnology services, examining pharmaceuticals, and selling precision instruments. Its products include GE Max Series, GE GM550, GlucoCapture Wiz Series, GlucoCapture Cielo Series, GlucoCapture Oro SEries, GE 100, GE 200, GE333, Test Strips, and Lancing Device. The company was founded by Chun Mu Huang on April 14, 2003 and is headquartered in Taichung, Taiwan.

Ownership
‪‪61.04 M‬‬
Free Float shares
‪‪49.49 M‬‬ (81.09%)
Closely held shares
‪‪11.54 M‬‬ (18.91%)
Free Float shares
‪‪49.49 M‬‬ (81.09%)
Closely held shares
‪‪11.54 M‬‬ (18.91%)
Capital structure
Market cap
‪‪3.78 B‬‬
Debt
‪‪2.95 B‬‬
Minority interest
‪‪8.97 M‬‬
Cash & equivalents
‪‪387.55 M‬‬
Enterprise value
‪‪6.36 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪3.78 B‬‬
Price to earning ratio (P/E)
Price to sales ratio (P/S)
2.04x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
Price to sales ratio (P/S)
2.04x
Valuation ratios
‪0.00‬
‪0.70‬
‪1.40‬
‪2.10‬
‪2.80‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪200.00‬
‪400.00‬
‪600.00‬
‪800.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−12%‬
‪−8%‬
‪−4%‬
‪0%‬
‪4%‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−170.00 M‬‬
‪0.00‬
‪‪170.00 M‬‬
‪‪340.00 M‬‬
‪‪510.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−170.00 M‬‬
‪0.00‬
‪‪170.00 M‬‬
‪‪340.00 M‬‬
‪‪510.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−170.00 M‬‬
‪0.00‬
‪‪170.00 M‬‬
‪‪340.00 M‬‬
‪‪510.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2023
Blood Sugar Detecting Test Piece
Other
Blood Sugar Detector
By country
Period: 2023
Other Countries
Algeria
China
United States
Switzerland
United Arab Emirates
Egypt

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q1 '25
‪0.00‬
‪‪150.00 M‬‬
‪‪300.00 M‬‬
‪‪450.00 M‬‬
‪‪600.00 M‬‬
Estimate
Earnings
Next:May 9, 2025
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q1 '25
‪−0.12‬
‪0.00‬
‪0.12‬
‪0.24‬
‪0.36‬
Estimate

Dividends

Dividend yield, history and sustainability

Dividend summary
−146.54%
Payout ratio (TTM)
Dividend yield TTM
3.13%
Last payment
1.999
Last ex-date
Jul 29, 2024
Dividend history
‪2.0%‬
‪2.3%‬
‪2.6%‬
‪2.9%‬
‪3.2%‬
2019
2020
2021
2022
2023
‪0.00‬
‪0.60‬
‪1.20‬
‪1.80‬
‪2.40‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−1.00 B‬‬
‪0.00‬
‪‪1.00 B‬‬
‪‪2.00 B‬‬
‪‪3.00 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪1.00 B‬‬
‪‪2.00 B‬‬
‪‪3.00 B‬‬
‪‪4.00 B‬‬
Assets
Liabilities